Point State Capital LP Intra Cellular Therapies, Inc. Transaction History

Point State Capital LP

  • $4.42 Billion
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2018

Nov 14, 2018
SELL
$17.77 - $22.9 $8.44 Million - $10.9 Million
-475,000 Closed
0 $0
Q2 2018

Aug 14, 2018
SELL
$17.33 - $23.4 $24.2 Million - $32.6 Million
-1,393,600 Reduced 74.58%
475,000 $8.39 Million
Q1 2018

May 15, 2018
BUY
$15.16 - $25.49 $28.3 Million - $47.6 Million
1,868,600 New
1,868,600 $39.3 Million

Others Institutions Holding ITCI

# of Institutions
419
Shares Held
88.8M
Call Options Held
284K
Put Options Held
105K
View Full List

About Intra-Cellular Therapies, Inc.

ITCI Quotes by TradingView
  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $12.4B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track Point State Capital LP Portfolio

Follow Point State Capital LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point State Capital LP, based on Form 13F filings with the SEC.

News

Stay updated on Point State Capital LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email